Skip to content
M

Mohamed Mahjoub

Publications (4)

Healthcare-Associated Infection Specificities’ in a Tunisian University Hospital: Overview of the Results

Mohamed Mahjoub, Amel Amara, Nabiha Bouafia, Sihem Ben Fredj, Amel Ben Abdeljalil & Mansour Njah · Journal of Advances in Medicine and Medical Research · 2017

Background: Our study was conducted, in university hospital center Farhat Hached of Sousse (city in Tunisian center-east), within healthcare-associated infections (HAI) epidemiological surveillance program. Aim: The aim of this study was to determine the healthcare-associated inf...

Open access Research Article 10.9734/JAMMR/2017/36829

Unscheduled Return Visits to the Emergency Department: Case of University Hospital Center in Tunisia

Zied Mezgar, Mariem Khrouf, Houda Ben Soltane, Mohamed Mahjoub, Amel Amara, Sihem Ben Fredj, Maher Jdidi, Samar Hajer Sandid, Sarra Zaouali, Ines Waz, Asma Saada & Mehdi Methamem · Journal of Advances in Medicine and Medical Research · 2018

Introduction: The re-consultation after short period of initial visit is an indicator of health care’s quality offered in the first consultation. They increase health expenditures and reflect a wrong medical care process. Aims: The aims of this work are to determine the rate of r...

Open access Research Article 10.9734/JAMMR/2017/38329

Synchronous Thyroid and Gastric Mantle Cell Lymphoma

Kmira Zahra, Rania Bouneb, Sarra Mestiri, Mohamed Mahjoub, Monia Zaier, Yosra Ben Youssef & Abderrahim Khelif · International Journal of Medical and Pharmaceutical Case Reports · 2016

Introduction: Mantle cell lymphoma (MCL) is a distinct entity within the World Health Organization classification of lymphoid neoplasm and represents approximately 8% of lymphoma. Patients with mantle-cell lymphoma typically present with extensive disease and involvement of multi...

Open access Research Article 10.9734/IJMPCR/2016/29229

Myocardial Infarction in a Young Patient with Chronic Myeloid Leukemia after Nilotinib Use

Neila Fathallah, Kmira Zahra, Rania Bouneb, Mohamed Mahjoub, Wafa Guetari, Monia Zaier, Chaker Ben Salem & Abderrahim Khelif · International Journal of Medical and Pharmaceutical Case Reports · 2016

Nilotinib is an analog of imatinib increasingly used for the treatment of imatinib-resistant chronic myeloid leukemia. It has been considered a well-tolerated drug with little side effects. The most common adverse effects to nilotinib are skin rash, pruritus, headache, nausea, an...

Open access Research Article 10.9734/IJMPCR/2016/28909